-
Study aim
-
A clinical trial on the effectiveness of intracoronary adenosine for the prevention of no-reflow phenomenon in patients with acute myocardial infarction
-
Design
-
In this pragmatic double-blind, controlled clinical trial, 126 patients with acute myocardial infarction were assigned into parallel groups using the table of random numbers in a community-based setting.
-
Settings and conduct
-
Patients with acute myocardial infarction at the Department of Cardiology, Ghaem Hospital, Mashhad, Iran, were chosen. In this double-blind study, the clinical care and data collector were blind to group assignment and the type of treatment.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: age older than 20 years; an elapse of 12 hours form the primary diagnosis.
Exclusion criteria: suffering chronic obstructive pulmonary disease, asthma, less than 90 mm Hg systolic blood pressure, cardiac arrhythmia, sick sinus syndrome and neuropathy; candidates for coronary artery bypass grafts; using other medicines, such as verapamil.
-
Intervention groups
-
The control group will receive 3 mcg adenosine in 50 cc normal saline. The low dose intervention group will receive 120 mcg adenosine for involvement of right coronary artery and 240 mcg adenosine for involvement of left coronary artery. The high dose intervention group will receive 240 mcg adenosine for involvement of right coronary artery and 480 mcg adenosine for involvement of left coronary artery.
-
Main outcome variables
-
Evaluation and comparison of major adverse cardiovascular events (i.e., mortality, second myocardial infarction, and stroke during admission), ejection fraction of ventricular, the reduction of ST-segment and thrombolysis in myocardial infarction flow before and 24 hours after the intervention in the intervention and control groups.